Evidence map›Paper›PMID 27619675›Full record

ArticleBMC cancer2016

Does native Trypanosoma cruzi calreticulin mediate growth inhibition of a mammary tumor during infection?

Paula Abello-Cáceres, Javier Pizarro-Bauerle, Carlos Rosas, Ismael Maldonado, Lorena Aguilar-Guzmán, Carlos González, Galia Ramírez, Jorge Ferreira, Arturo Ferreira

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 30 citations in OpenAlex.

  1. Bugs as drugs: parasite biomolecules as novel therapeutics against breast cancer.American journal of physiology. Cell physiology · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Parasites revive hope for cancer therapy.European journal of medical research · 2024
    Review
  6. Review
  7. Tumor-Suppressive Cross-Linking of Anti-International journal of molecular sciences · 2024
    Article
  8. Review
  9. Cytotoxic Effect ofAdvances in pharmacological and pharmaceutical sciences · 2024
    Article
  10. Parasites as potential targets for cancer immunotherapy.Journal of cancer research and clinical oncology · 2023
    Review
  11. Frontiers in cell and developmental biology · 2023
    Review
  12. A novel enemy of cancer: recent investigations into protozoan anti-tumor properties.Frontiers in cellular and infection microbiology · 2023
    Review
  13. The many faces of parasite calreticulin.Frontiers in immunology · 2023
    Review
  14. Pharmaceuticals (Basel, Switzerland) · 2022
    Article
  15. Comorbidities involving parasitic diseases: A look at the benefits and complications.Experimental biology and medicine (Maywood, N.J.) · 2022
    Review
  16. Is It Possible to Intervene in the Capacity ofFrontiers in immunology · 2021
    Review
  17. Review
  18. Review
  19. Frontiers in microbiology · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Paula Abello-CáceresInstitute of Biomedical Sciences (ICBM), Faculty of Medicine, University of Chile, Avenida Independencia 1027, Independencia, Santiago, Chile.
Javier Pizarro-BauerleInstitute of Biomedical Sciences (ICBM), Faculty of Medicine, University of Chile, Avenida Independencia 1027, Independencia, Santiago, Chile.
Carlos RosasInstitute of Biomedical Sciences (ICBM), Faculty of Medicine, University of Chile, Avenida Independencia 1027, Independencia, Santiago, Chile.
Ismael MaldonadoInstitute of Biomedical Sciences (ICBM), Faculty of Medicine, University of Chile, Avenida Independencia 1027, Independencia, Santiago, Chile.
Lorena Aguilar-GuzmánFaculty of Veterinary Medicine and Livestock Sciences, University of Chile, Avenida Santa Rosa 11735, La Pintana, Santiago, Chile.
Carlos GonzálezFaculty of Veterinary Medicine, Andrés Bello University, Avenida República 440, Santiago Centro, Santiago, Chile.
Galia RamírezFaculty of Veterinary Medicine and Livestock Sciences, University of Chile, Avenida Santa Rosa 11735, La Pintana, Santiago, Chile.
Jorge FerreiraInstitute of Biomedical Sciences (ICBM), Faculty of Medicine, University of Chile, Avenida Independencia 1027, Independencia, Santiago, Chile.
Arturo FerreiraInstitute of Biomedical Sciences (ICBM), Faculty of Medicine, University of Chile, Avenida Independencia 1027, Independencia, Santiago, Chile. aferreira_uchile@yahoo.com.
University of Chile · CLUniversidad Andrés Bello · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFor several decades now an antagonism between Trypanosoma cruzi infection and tumor development has been detected. The molecular basis of this phenomenon remained basically unknown until our proposal that T. cruzi Calreticulin (TcCRT), an endoplasmic reticulum-resident chaperone, translocated-externalized by the parasite, may mediate at least an important part of this effect. Thus, recombinant TcCRT (rTcCRT) has important in vivo antiangiogenic and antitumor activities. However, the relevant question whether the in vivo antitumor effect of T. cruzi infection is indeed mediated by the native chaperone (nTcCRT), remains open. Herein, by using specific modified anti-rTcCRT antibodies (Abs), we have neutralized the antitumor activity of T. cruzi infection and extracts thereof, thus identifying nTcCRT as a valid mediator of this effect.

methodsPolyclonal anti-rTcCRT F(ab')2 Ab fragments were used to reverse the capacity of rTcCRT to inhibit EAhy926 endothelial cell (EC) proliferation, as detected by BrdU uptake. Using these F(ab')2 fragments, we also challenged the capacity of nTcCRT, during T. cruzi infection, to inhibit the growth of an aggressive mammary adenocarcinoma cell line (TA3-MTXR) in mice. Moreover, we determined the capacity of anti-rTcCRT Abs to reverse the antitumor effect of an epimastigote extract (EE). Finally, the effects of these treatments on tumor histology were evaluated.

resultsThe rTcCRT capacity to inhibit ECs proliferation was reversed by anti-rTcCRT F(ab')2 Ab fragments, thus defining them as valid probes to interfere in vivo with this important TcCRT function. Consequently, during infection, these Ab fragments also reversed the in vivo experimental mammary tumor growth. Moreover, anti-rTcCRT Abs also neutralized the antitumor effect of an EE, again identifying the chaperone protein as an important mediator of this anti mammary tumor effect. Finally, as determined by conventional histological parameters, in infected animals and in those treated with EE, less invasive tumors were observed while, as expected, treatment with F(ab')2 Ab fragments increased malignancy.

conclusionWe have identified translocated/externalized nTcCRT as responsible for at least an important part of the anti mammary tumor effect of the chaperone observed during experimental infections with T. cruzi.

Indexed as

AnimalsAntibodies, NeutralizingCalreticulinCell LineCell ProliferationEndothelial CellsFemaleMammary Neoplasms, ExperimentalMiceProtozoan ProteinsTrypanosoma cruziTrypanosomiasisAntibodies, NeutralizingCalreticulinProtozoan ProteinsAngiogenesisCalreticulinMammary tumorTrypanosoma cruzi

Identifiers

PMID27619675
PMCPMC5020520
OpenAlexW2519014474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.